Cellavita HD Higher dose ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
8 | ハンチントン病 | 2 |
8. ハンチントン病
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03252535 (ClinicalTrials.gov) | January 15, 2018 | 15/8/2017 | Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease | Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease | Huntington Disease | Biological: Cellavita HD lower dose;Biological: Cellavita HD higher dose;Other: Placebo | Azidus Brasil | Cellavita Pesquisa Científica Ltda | Completed | 21 Years | 65 Years | All | 35 | Phase 2 | Brazil |
2 | NCT02728115 (ClinicalTrials.gov) | October 16, 2017 | 11/3/2016 | Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease | First in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's Disease | Huntington Disease | Biological: Cellavita HD Lower Dose;Biological: Cellavita HD Higher dose | Azidus Brasil | Cellavita Pesquisa Científica Ltda;Azidus Brasil Scientific Research and Development Ltda | Active, not recruiting | 21 Years | 65 Years | Male | 6 | Phase 1 | Brazil |